Dr. Mok Discusses Next Steps With Pembrolizumab in NSCLC
Tony Mok, MD, discusses the next steps for pembrolizumab (Keytruda) as a treatment option for patients with non-small cell lung cancer after the phase III KEYNOTE-042 trial.